About Us

Mission

The mission of the Working Group on New TB Vaccines is to facilitate research and development of new vaccines to prevent TB by providing an inclusive forum for stakeholders to engage in scientific exchange, build consensus on key issues, and advocate for greater support and investment in TB vaccine R&D.

About the WGNV

The Working Group on New TB Vaccines (WGNV) was established in 2001. It is one of the nine Working Groups of the Stop TB Partnership. Its purpose is to facilitate the development of new, more effective TB vaccines through collaboration, cooperation, and consensus; and to support the objectives for TB vaccine R&D in the Global Plan to End TB 2016-2020.

The WGNV is an informal network of stakeholders engaged in all aspects of TB vaccine R&D and from all constituencies, including academics, product developers, clinicians, advocates, and affected communities. Membership is open to anyone who is interested in being engaged and involved in TB vaccine R&D.

Our Work

The WGNV plays a unique role as a network of stakeholders who support the goal of developing new TB vaccines. It provides a forum for dialogue on issues relevant to research, development and advocacy for new TB vaccines; facilitates coordinated activities to support the objectives and milestones outlined in the Global Plan to End TB; convenes stakeholders to discuss key issues related to vaccine development; serves as an objective source of information on TB vaccines and vaccine development; and advocates for increased investment in and support for new TB vaccine development.The WGNV has made several contributions to TB vaccine R&D in this role, including:

  • Development and publication of a consensus statement on diagnostic endpoints for infant tuberculosis vaccine trials (Clin Infect Dis 2012; 54:493-501);
  • Publication of Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade, following a year-long consultative process on key challenges and priorities for TB vaccine R&D. Tuberculosis 2012: Volume 92, Supplement 1: S1-S35;
  • Convening the Global Forum on TB Vaccines in Tallinn, Estonia (Sept 2010); Cape Town, South Africa (March 2013); and Shanghai, China (April 2015). The 5th Global Forum will take place in New Delhi, India from 20-23 February 2018.
  • Developing the vaccines section of the Global Plan to End TB 2016-2020 through an inclusive process with stakeholders;
  • Representing the TB vaccine research community and providing updates on the state of the field at meetings and international events.
  • Building capacity and research literacy of advocates through a newly launched TB vaccine R&D advocacy program.

Leadership

The WGNV is led by a Chair, two Co-Chairs, and a Core Group representing the many constituencies involved in TB vaccine R&D.

Learn More

Get Involved

If you would like to learn more about the WGNV and how you can be, please contact us!

Contact Us